Mikey Graham (Boyzone) lost 3 stone with Mounjaro ahead of the band’s two-night farewell at Emirates Stadium on 5 and 6 June 2026. The NHS England tirzepatide rollout began in April 2026 – this is a calm explainer on what the medication does, who is eligible, what the trial data show, and how to access it safely.

Mikey Graham’s 3-Stone Boyzone Comeback Weight Loss UK 2026: Mounjaro, the NHS Rollout and What the Evidence Shows

You are a Boyzone fan. Mid-June 2026, scrolling through your phone, you see photographs of Mikey Graham looking notably slimmer ahead of the band’s farewell shows at the Emirates Stadium. He says he lost three stone and credits Mounjaro. You wonder whether the same treatment could help you.

Perhaps a partner or parent has asked the same question after seeing the same headline. Or perhaps you are someone with a BMI of 32 who has already tried Slimming World, a GP weight clinic and more Mediterranean recipes than you care to count, and you are considering whether to ask for a prescription.

This article is written for any of those readers. It walks through what Mikey Graham actually said in his interviews, what tirzepatide is and how it works in the body, how the NHS England April 2026 rollout operates in practice, who is eligible right now, what published trial data show about realistic weight loss, what side effects to expect, what private UK access costs, and the safety points worth settling before starting any GLP-1 medication.

What Mikey Graham actually said about his Boyzone weight loss

In interviews with Dublin City FM, Classic Hits Ireland and RSVP Magazine ahead of Boyzone’s two-night farewell at the Emirates Stadium on 5 and 6 June 2026, Mikey Graham said he had lost three stone — approximately 19 kg or 42 pounds — so that he could perform at his best for fans on stage. He is 53 years old. He described the previous few years as a very difficult period that included comfort eating, and he credited Mounjaro, the brand name for tirzepatide, with helping him to lose the weight.

Graham had previously stayed away from the 2025 Boyzone: No Matter What documentary and had not spoken to former bandmates Ronan Keating, Keith Duffy and Shane Lynch for around five years before reconciling for the farewell shows. The two Emirates dates marked the band’s official end after a 32-year career that included Father and Son, Words, and No Matter What.

The purpose of including this section is not celebrity gossip. It is to anchor the rest of the article in a UK-specific, recent, well-publicised real-world case. Interest in tirzepatide reliably rises after celebrity disclosures. The risk is that the conversation never gets past the headline. The rest of this piece is the conversation past the headline.

What Mounjaro (tirzepatide) actually is and how it works

Tirzepatide is a once-weekly subcutaneous injection marketed by Eli Lilly under the brand name Mounjaro for weight management, with a separate licence for type 2 diabetes. It is a dual agonist, meaning it activates two gut-hormone receptors at the same time. The first is GLP-1 (glucagon-like peptide 1), the same receptor activated by semaglutide, which is sold as Ozempic and Wegovy. The second is GIP (glucose-dependent insulinotropic polypeptide), a second receptor that contributes additional appetite suppression and metabolic effects. This dual-action mechanism distinguishes tirzepatide from semaglutide.

The combined action produces stronger appetite reduction, slower gastric emptying, lower food cravings — sometimes described by patients as quietening “food noise” — and improved insulin response after meals.

In the UK, Mounjaro is supplied as pre-filled single-use pens at doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg. The standard protocol is to start at 2.5 mg weekly for the first four weeks. This starting dose is for tolerability rather than meaningful weight loss. The dose then steps up to 5 mg, then 7.5 mg or higher in four-week increments depending on response and side effects. Maintenance doses are usually 10 mg or 15 mg weekly. Injection sites rotate between the abdomen, thigh and upper arm. Most people learn the technique in a five-minute clinic appointment. The pen is stored in a refrigerator until first use and can then be kept at room temperature for up to 21 days.

How the NHS England April 2026 tirzepatide rollout works

NICE Technology Appraisal 1026 approved tirzepatide on the NHS for weight management in late 2024. From 1 April 2026 NHS England formally incorporated tirzepatide prescribing into the 2026-27 GP contract via new Quality and Outcomes Framework indicators. Funded provision flows through Tier 3 specialist weight management services and, from this year, through primary care under defined eligibility tiers that broaden over 36 months.

The most restrictive tier, active from June 2026, reserves NHS-funded tirzepatide for adults with a BMI of 35 or above plus four of five weight-related comorbidities: type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, and established cardiovascular disease. From 2027, the criteria broaden to BMI 35 or above with three comorbidities. From 2028, the threshold becomes BMI 35 or above with any one comorbidity. People from defined higher-risk ethnic groups — including South Asian, Chinese, Black African, African-Caribbean and Middle Eastern backgrounds — qualify at lower BMI thresholds throughout.

The Tier 3 pathway includes multidisciplinary team support: dietetics, psychology, exercise advice and medication assessment over at least 12 months. To start, see your GP and request a Tier 3 referral. Not every GP practice will be commissioned to prescribe under the QOF indicators in 2026; participation varies by Integrated Care Board. If you do not meet the current NHS criteria but want to access tirzepatide, the private route remains available.

What weight loss can you realistically expect on Mounjaro

The SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, randomised 2,539 adults with a BMI of 30 or above — without type 2 diabetes — to weekly tirzepatide at 5 mg, 10 mg or 15 mg, or placebo, for 72 weeks. Mean body weight reduction was 15.0 percent on 5 mg, 19.5 percent on 10 mg, and 22.5 percent on 15 mg, compared with 2.4 percent on placebo. For an average UK adult starting at around 105 kg, the 15 mg result translates to roughly 23 kg or about 50 lb.

SURMOUNT-2, which studied people with type 2 diabetes, showed 15.7 percent weight loss at 15 mg. SURMOUNT-3 and SURMOUNT-4 explored the maintenance phase and found that most weight loss persists if treatment continues, with weight regain typical if the medication is stopped.

Mikey Graham’s 3-stone loss, around 19 kg, sits in the 15 to 20 percent range for someone starting between 90 and 110 kg and is a realistic outcome at 10 to 15 mg weekly over 6 to 12 months. Real-world UK private clinic data has averaged 15 to 20 percent at 12 months, slightly below the trial mean, which is consistent with international real-world experience.

The published trial data show that most of the loss is fat, but lean mass loss is also documented. Protecting muscle requires adequate protein intake — 1.2 to 1.6 g per kg of ideal body weight per day — and resistance training two to three times a week. Without these measures, the body composition outcome is less favourable than the number on the scale suggests.

Common side effects and the more serious risks to know

Gastrointestinal effects are the most frequent side effects reported in SURMOUNT-1 and in FDA labelling. Nausea occurs in 25 to 29 percent of users, diarrhoea in 20 to 23 percent, constipation in 15 to 20 percent, vomiting in 10 to 13 percent, and indigestion or dyspepsia in 8 to 12 percent. Decreased appetite, reported in 10 to 15 percent, is largely intended. Most of these effects are mild to moderate, peak during the first 8 to 12 weeks of dose titration, and improve with smaller meals, slower eating, adequate hydration, and avoiding rich or fatty foods on injection day.

Less common but more serious risks exist and deserve attention before starting. Pancreatitis is rare but serious — stop tirzepatide immediately and seek urgent care if you develop persistent severe upper abdominal pain that radiates to the back, particularly with vomiting. Gallbladder disease risk is modestly increased, especially during rapid weight loss; watch for right-upper-quadrant pain, fever and jaundice. Medullary thyroid carcinoma is a US black-box warning based on animal data; absolute risk in humans appears very low, but tirzepatide must not be used by anyone with a personal or family history of medullary thyroid cancer or MEN2 syndrome.

Diabetic retinopathy progression has been observed in people with pre-existing retinopathy, so an eye review is sensible before starting if relevant. Kidney injury is usually a consequence of severe dehydration from persistent vomiting. The EMA and MHRA investigated a mood and suicidal-ideation signal across GLP-1 medications in 2024 and 2025. No causal association has been established but pharmacovigilance monitoring continues. Report any new low mood or self-harm thoughts to your GP promptly.

How to access tirzepatide in the UK in 2026 (NHS vs private vs avoiding fakes)

The NHS route begins with seeing your GP and requesting a referral to Tier 3 weight management if you meet the current eligibility criteria — BMI of 35 or above plus four comorbidities from the defined list in the June 2026 tier. If your BMI is lower or you have fewer comorbidities, the criteria broaden through 2027 and 2028. Tier 3 includes a dietitian, psychologist, exercise specialist and medical input, which is structured care that improves outcomes regardless of whether medication is prescribed.

The private route is available through registered UK online weight loss clinics and pharmacies offering Mounjaro via remote consultation. The realistic monthly cost at maintenance dose in mid-2026 is 150 to 250 pounds, with starter packs typically 100 to 150 pounds for the first month. Always check the General Pharmaceutical Council register at pharmacyregulation.org to verify that the pharmacy holds a valid UK licence before paying. Numan, Bolt Pharmacy, Boots Online Doctor, Pharmacy2U, Lloyds Online Pharmacy and Superdrug Online Doctor all operate legitimate UK Mounjaro consultation services.

Avoid social-media sellers, Telegram and WhatsApp groups, unbranded “weight loss pen” adverts on Instagram, and any seller without a verifiable GPhC registration number. The MHRA has issued multiple warnings about counterfeit Mounjaro pens. Some contain incorrect doses, no active ingredient, or unknown adulterants. UK hospital admissions from counterfeit pens have been documented. The typical price difference between a legitimate registered online pharmacy and a social-media seller is 30 to 80 pounds per month. The safety difference is far greater.

Frequently Asked Questions

How much weight did Mikey Graham lose with Mounjaro and over how long?

Mikey Graham lost approximately 3 stone — around 19 kg or 42 lb — ahead of Boyzone’s farewell concerts at the Emirates Stadium on 5 and 6 June 2026. He has not disclosed the exact treatment duration, but a 3-stone loss is consistent with 6 to 12 months of weekly tirzepatide at 10 mg or 15 mg dosing for someone in the 90 to 110 kg starting weight range. He credited Mounjaro and described the previous years as very difficult, including a period of comfort eating.

Can I get Mounjaro on the NHS in 2026?

Yes, if you meet the June 2026 NHS England eligibility tier — a BMI of 35 or above plus four of five weight-related comorbidities: type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or established cardiovascular disease. People from higher-risk ethnic groups qualify at lower BMI thresholds. Access is via GP referral to a Tier 3 specialist weight management service. Eligibility broadens in 2027 to BMI 35 with three comorbidities, and in 2028 to BMI 35 with any one comorbidity.

What does Mounjaro cost privately in the UK in 2026?

The realistic private cost in mid-2026 is 150 to 250 pounds per month at maintenance dose, with starter packs typically 100 to 150 pounds for the first month. Numan, Bolt Pharmacy, Boots Online Doctor, Pharmacy2U, Lloyds Online Pharmacy and Superdrug Online Doctor all offer legitimate UK consultations. Always verify the GPhC registration at pharmacyregulation.org before paying. Avoid social-media sellers — the MHRA has issued repeated warnings about counterfeit Mounjaro pens containing incorrect doses, no active ingredient, or unknown adulterants.

What are the most common side effects of Mounjaro?

Gastrointestinal effects dominate. Nausea affects 25 to 29 percent of users, diarrhoea 20 to 23 percent, constipation 15 to 20 percent, vomiting 10 to 13 percent, and indigestion 8 to 12 percent. Most are mild to moderate, peak during titration in the first 8 to 12 weeks, and improve with smaller meals, slower eating, hydration, and avoiding rich foods on injection day. Rare but serious risks include pancreatitis, gallbladder disease and possible diabetic retinopathy progression. Stop tirzepatide and seek urgent care for persistent severe abdominal pain radiating to the back.

Will I regain the weight if I stop Mounjaro?

Often, yes. SURMOUNT-3 and 4 trial data show meaningful weight regain in most people who discontinue tirzepatide, typically returning to within 5 to 10 percent of baseline within 12 months. This is consistent with how other chronic disease medications behave — stopping blood pressure tablets brings blood pressure back up. Most people who succeed on tirzepatide stay on a maintenance dose long-term. Protecting against rebound requires continuing the dietary and activity habits established during weight loss, alongside regular medical review.

Who should NOT take Mounjaro?

Do not take tirzepatide if you have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, severe gastroparesis, type 1 diabetes (not licensed for this condition), or active pancreatitis. Avoid in pregnancy and during the two months before planned conception. Avoid while breastfeeding due to insufficient safety data. Use barrier or progestogen-only contraception when starting, as tirzepatide can reduce the absorption of combined oral contraceptives. People with a history of pancreatitis, severe gastrointestinal disease, or active eating disorders should discuss the risks with a specialist before starting.

This article is informational only and does not replace personalised advice from your GP, pharmacist, or another qualified healthcare professional. Walton Surgery is not affiliated with Eli Lilly, Boyzone, or any third-party clinic or pharmacy mentioned.